Syndax Pharmaceuticals Inc 1T3
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 1T3 is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $19.20
- Day Range
- $18.80–18.80
- 52-Week Range
- —–26.60
- Bid/Ask
- $18.70 / $19.10
- Market Cap
- $1.60 Bil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 184
- Website
- https://www.syndax.com
Comparables
Valuation
|
Metric
|
1T3
|
CLDX
|
ITOS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.58 | 2.72 | 1.07 |
Price/Sales | — | 293.27 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
1T3
CLDX
ITOS
Financial Strength
|
Metric
|
1T3
|
CLDX
|
ITOS
|
|---|---|---|---|
Quick Ratio | 8.87 | 31.44 | 12.80 |
Current Ratio | 8.93 | 31.77 | 13.51 |
Interest Coverage | −1,182.75 | — | — |
Quick Ratio
1T3
CLDX
ITOS
Profitability
|
Metric
|
1T3
|
CLDX
|
ITOS
|
|---|---|---|---|
Return on Assets (Normalized) | −42.31% | −23.59% | −16.56% |
Return on Equity (Normalized) | −46.19% | −25.21% | −18.86% |
Return on Invested Capital (Normalized) | −51.17% | −25.04% | −22.78% |
Return on Assets
1T3
CLDX
ITOS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Yqnyvlvv | Ybcyb | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dnbdjsyjy | Bnkqt | $114.2 Bil | |||
| Moderna Inc
MRNA
| Dfjtppcj | Mtzp | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Zfqsschqp | Jch | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Vxvlwzzhq | Lpfj | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jkxxjpd | Zmlpls | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Cxnpvkv | Wqxrgcy | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Zxdqmbwtm | Ztsz | $12.8 Bil | |||
| Incyte Corp
INCY
| Hdcqrxnm | Twpgt | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Kbdgxtbnq | Drqsf | $12.2 Bil |